SOLLEY, WAYNE M.D.
Ophthalmology · NPI 1528042447 · ARLINGTON, TX
SOLLEY, WAYNE is a Ophthalmology in ARLINGTON, TX, a member of 1 medical group, who billed 22 distinct codes to Medicare Part B in 2024.
Groups: TEXAS RETINA ASSOCIATES (DALLAS, TX)
Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒
Provider overview · all codes · CY2024
All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.
Procedures billed to Medicare Part B (2024)
Medicare Part B FFS · CY2024 · as published by CMS| Code | Description | Services | Beneficiary-episodes | Avg charge | Avg Medicare payment |
|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | premium | premium | premium | premium |
| J2782 | Injection, avacincaptad pegol, 0.1 mg | premium | premium | premium | premium |
| 92134 | Imaging of retina | premium | premium | premium | premium |
| J0178 | Injection, aflibercept, 1 mg | premium | premium | premium | premium |
| 92014 | Established patient complete exam of visual system | premium | premium | premium | premium |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | premium | premium | premium | premium |
| 67028 | Injection of drug into eye | premium | premium | premium | premium |
| J2778 | Injection, ranibizumab, 0.1 mg | premium | premium | premium | premium |
| 99204 | New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more | premium | premium | premium | premium |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | premium | premium | premium | premium |
| 92012 | Established patient problem focused exam of visual system | premium | premium | premium | premium |
| J7999 | Compounded drug, not otherwise classified | premium | premium | premium | premium |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | premium | premium | premium | premium |
| J3490 | Unclassified drugs | premium | premium | premium | premium |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | premium | premium | premium | premium |
| 67145 | Photocoagulation treatment to prevent detachment of retina | premium | premium | premium | premium |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | premium | premium | premium | premium |
| 92250 | Photography of the retina | premium | premium | premium | premium |
| 76512 | 2d ultrasound scan of eye tissue and structures | premium | premium | premium | premium |
| 92201 | Extended exam of the back part of the eye with retinal drawing | premium | premium | premium | premium |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | premium | premium | premium | premium |
| 99203 | New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more | premium | premium | premium | premium |
These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.